The three-component helicase/primase complex of herpes simplex virus-1

Oya Bermek and R. Scott Williams

Genome Integrity and Structural Biology Laboratory, Department of Health and Human Services, National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC 27709, USA

The three-component helicase/primase complex of herpes simplex virus-1 is one of the nine herpesviruses that infect humans. HSV-1 encodes seven proteins to replicate its genome in the hijacked human cell. Among these are the herpes virus DNA helicase and primase that are essential components of its replication machinery. In the HSV-1 replisome, the helicase–primase complex is composed of three components including UL5 (helicase), UL52 (primase) and UL8 (non-catalytic subunit). UL5 and UL52 subunits are functionally interdependent, and the UL8 component is required for the coordination of UL5 and UL52 activities proceeding in opposite directions with respect to the viral replication fork. Anti-viral compounds currently under development target the functions of UL5 and UL52. Here, we review the structural and functional properties of the UL5/UL8/UL52 complex and highlight the gaps in knowledge to be filled to facilitate molecular characterization of the structure and function of the helicase–primase complex for development of alternative anti-viral treatments.

1. Introduction

Herpesviridae is a large family of approximately 100 double-stranded (ds) DNA viruses including nine that infect humans [1]. Herpesviruses are subdivided into alpha (α), beta (β) and gamma (γ) herpesvirinae [2]. The three subfamilies differ in the extent of genetic similarities, site of infection and length of cytolytic productive cycle [3]. A common feature among all herpesviruses is that following primary infection, the virus establishes lifelong latency in the infected person.

Herpesvirus infections are a complex threat to human health. In immunocompetent individuals, lytic (productive) herpesvirus infections result in an array of clinical presentations ranging from cold sores, genital lesions and chickenpox to mononucleosis and roseola (table 1). Moreover, in individuals with suppressed immune systems including neonates and those with diabetes, AIDS or cancer, opportunistic herpesvirus infections can cause life-threatening conditions. Herpes simplex virus 1 and 2 (HSV-1 and HSV-2) infections increase the risk of HIV infection [4,5]. In pregnant women, human cytomegalovirus (HCMV) can cause significant morbidity to fetuses and neonates [6]. Reactivation of latent human herpesvirus 6 and 7 (HHV-6 and HHV-7) infection, common after solid organ transplantation, has been associated with bone marrow suppression, encephalitis and pneumonitis [7]. Epstein–Barr virus (EBV) increases the risk of Hodgkin’s lymphoma [8]. Kaposis’s sarcoma caused by Kaposis’s sarcoma-associated herpesvirus (KSHV) is the most common cancer in untreated AIDS patients [9]. The broad spectrum of illness linked to herpesvirus infections necessitates further molecular characterization of the herpes virus life cycle and the development of novel therapeutics.

Most of the current drugs against herpesviruses target the virus-encoded DNA polymerase. These agents have been successfully used to treat HSV infections for decades, albeit less efficiently against varicella zoster herpesvirus (VZV) [10]. However, drug resistance developed by HSV poses a major problem...
for their effectiveness [11]. By contrast to the safety of HSV drugs, ganciclovir used for HCMV treatment has cytotoxic effects [12]. There are no therapies for HHV-6, HHV-7, EBV and KHSV. Herpesvirus infections remain a serious threat to human health, underscoring the need for characterization of the molecular mechanisms of herpes virus replication, with the goal of developing novel treatments for these widespread diseases.

The linear, double-stranded HSV-1 genome (152 kb) encodes as many as 284 open reading frames [13] of which seven gene products are dedicated to replicate its own genome in the infected human cell [14–16]. The essential gene products include the origin-binding protein (UL9), the core replisome composed of the single-strand DNA-binding protein (ICP8), UL30 (DNA polymerase) and UL42 (processivity factor) genes, and the heterotrimeric primosome encoded by the UL5 (helicase), UL52 (primase) and UL8 (non-catalytic subunit) genes (table 2). These genes are all located within the long unique (UL) region of the genome, and they were named according to their genomic locations [14]. The primary amino acid sequence of six core genes is conserved among all animal and human herpesviruses. The high-level amino acid sequence conservation observed for the replication machinery implies that all human herpesviruses share the same lytic replication mechanism.

HSV-1 is the most studied member of human herpesviruses. Initially, the functions of herpesvirus replication proteins have been examined in the HSV-1/2 and VZV systems. However, it has become clear that herpesvirus infections remain a serious threat to human health, underscoring the need for characterization of the molecular mechanisms of herpes virus replication, with the goal of developing novel treatments for these widespread diseases.

### Table 1. Herpesviridae infections. Abbreviations: Alpha (alphaherpesvirinae): HSV-1 (herpes simplex virus type 1), HSV-2 (herpes simplex virus type 2), VZV (varicella zoster virus); Beta (betaherpesvirinae): HCMV (human cytomegalovirus), HHV-6A (human herpesvirus 6A), HHV-6B (human herpesvirus 6B), HHV-7 (human herpesvirus 7); Gamma (gammaherpesvirinae): EBV (epstein–Barr virus), KSHV (Kaposi’s sarcoma-associated herpesvirus).

| subfamily | virus | symptoms in immunocompetent hosts | symptoms in immunocompromised hosts |
|-----------|-------|---------------------------------|-----------------------------------|
| Alpha     | HSV-1 | herpes labialis, gingivostomatitis, keratoconjunctivitis, cutaneous herpes, genital herpes, encephalitis, viral meningitis | oesophagitis, pneumonia, disseminated infection, hepatitis |
|           | HSV-2 | genital herpes, cutaneous herpes, gingivostomatitis, neonatal herpes, viral meningitis | disseminated infection, hepatitis, encephalitis |
|           | VZV   | varicella (chickenpox), herpes zoster (shingles), viral meningitis | disseminated herpes zoster |
| Beta      | HCMV  | mononucleosis-like illness, hepatitis, cytomegalic inclusion disease, carditis | encephalitis, hepatitis, retinitis, pneumonia, colitis, gastrointestinal diseases, central nervous system diseases, pancreatitis, nephritis, allograft infections, oesophagitis |
|           | HHV-6 | roseola infantum, otitis media with fever | encephalitis, interstitial pneumonitis, partial myelosuppression, delayed engraftment, high-grade graft-versus-host-disease |
|           | HHV-7 | roseola infantum | encephalitis |
| Gamma     | EBV   | infectious mononucleosis, hepatitis, encephalitis, nasopharyngeal carcinoma, Burkitt’s lymphoma, Hodgkin’s lymphoma | lymphoproliferative syndromes, oral hairy leukoplakia, non-Hodgkin lymphoma |
|           | KHSV  | | Kaposi’s sarcoma, AIDS-related non-Hodgkin lymphoma, primary effusion lymphoma, multicentric Castleman disease, inflammatory cytokine syndrome |

### Table 2. Herpesviridae replication proteins in all nine human herpesviruses. NCBI’s reference sequence (RefSeq) accession numbers of HSV-1 replication proteins: UL30 (YP_009137105.1), UL42 (YP_009137117.1), ICP8 (YP_009137104), UL5 (YP_009137079.1), UL52 (YP_009137128), UL8 (YP_009137082). ICP8 is the UL29 gene product. BBLF2/BBLF3 and ORF40/ORF41 are spliced transcripts.

| function                                      | Alpha          | Beta         | Gamma         |
|-----------------------------------------------|----------------|--------------|---------------|
| DNA polymerase catalytic subunit              | UL30           | UL54         | BALF5         |
| DNA polymerase processivity subunit           | UL42           | UL44         | BMRF1         |
| single-strand DNA-binding protein             | ICP8           | UL57         | BFL2          |
| helicase/primase helicase subunit             | UL5            | UL105        | BBLF4         |
| helicase/primase primase subunit              | UL52           | UL70         | BSLF1         |
| helicase/primase subunit                      | UL8            | UL102        | BBLF2/BBLF3   |

for their effectiveness [11]. By contrast to the safety of HSV drugs, ganciclovir used for HCMV treatment has cytotoxic effects [12]. There are no therapies for HHV-6, HHV-7, EBV and KHSV. Herpesvirus infections remain a serious threat to human health, underscoring the need for characterization of the molecular mechanisms of herpes virus replication, with the goal of developing novel treatments for these widespread diseases.

The linear, double-stranded HSV-1 genome (152 kb) encodes as many as 284 open reading frames [13] of which seven gene products are dedicated to replicate its own genome in the infected human cell [14–16]. The essential gene products include the origin-binding protein (UL9), the core replisome composed of the single-strand DNA-binding protein (ICP8), UL30 (DNA polymerase) and UL42 (processivity factor) genes, and the heterotrimeric primosome encoded by the UL5 (helicase), UL52 (primase) and UL8 (non-catalytic subunit) genes (table 2). These genes are all located within the long unique (UL) region of the genome, and they were named according to their genomic locations [14]. The primary amino acid sequence of six core genes is conserved among all animal and human herpesviruses. The high-level amino acid sequence conservation observed for the replication machinery implies that all human herpesviruses share the same lytic replication mechanism.

HSV-1 is the most studied member of human herpesviruses. Initially, the functions of herpesvirus replication proteins have been examined in the HSV-1/2 and VZV systems. However, it has become clear that herpesvirus infections remain a serious threat to human health, underscoring the need for characterization of the molecular mechanisms of herpes virus replication, with the goal of developing novel treatments for these widespread diseases.

The linear, double-stranded HSV-1 genome (152 kb) encodes as many as 284 open reading frames [13] of which seven gene products are dedicated to replicate its own genome in the infected human cell [14–16]. The essential gene products include the origin-binding protein (UL9), the core replisome composed of the single-strand DNA-binding protein (ICP8), UL30 (DNA polymerase) and UL42 (processivity factor) genes, and the heterotrimeric primosome encoded by the UL5 (helicase), UL52 (primase) and UL8 (non-catalytic subunit) genes (table 2). These genes are all located within the long unique (UL) region of the genome, and they were named according to their genomic locations [14]. The primary amino acid sequence of six core genes is conserved among all animal and human herpesviruses. The high-level amino acid sequence conservation observed for the replication machinery implies that all human herpesviruses share the same lytic replication mechanism.

HSV-1 is the most studied member of human herpesviruses. Initially, the functions of herpesvirus replication
proteins were inferred from homology with HSV-1 proteins. In the last 20 years, the number of HSV-1 homologues that have been characterized in HCMV, EBV and KHSV has expanded. The homologues of UL30 [17–19], UL42 [19–22], ICP8 [23,24] and UL5/UL8/UL52 [25,26] have been purified, and their functions were confirmed to be aligned with that of HSV-1 proteins. However, HSV-1 remains one of the best characterized of the viral replication cycles. In this model replication system, six purified HSV-1 proteins can synthesize in vitro long concatemeric DNA products from a minicircular DNA substrate [27–29]. Despite these advances, precisely how the replisome assembles is not fully understood.

During infection, viral DNA is released from the capsid into the nucleus where viral DNA replication occurs [30]. Electron microscopy analysis reported that in vivo herpesvirus replication intermediates are linear concatemeric DNA molecules arranged in a head-to-tail fashion [31]. At later stages of infection, replication intermediates become highly branched DNA structures with X- and Y-junctions [32–36]. The first stage of HSV lytic replication was proposed to follow an origin-dependent replication (theta replication), involving the origin-binding protein UL9. However, theta-type replication DNA intermediates have not yet been observed either in vivo or in vitro. At least six replication proteins are recruited to the viral replication fork. The precise mechanism of replication remains controversial. Purified replication proteins can generate in vitro long concatemeric DNA products from a circular substrate [27–29]. As implied from in vitro data, the concatemeric replication intermediates could be formed by a rolling-circle replication. They could also be formed by a recombination-dependent replication [37–39].

For an efficient viral DNA synthesis, the enzymatic reactions proceeding in opposite directions of the replication fork must be coordinated. Figure 1 presents a model for the architecture of the HSV-1 replisome for coordinated leading- and lagging-strand synthesis. However, the configuration of HSV replication proteins at the replication fork is not known, as the atomic resolution structure of the replisome has not yet been determined. Thus far, the crystal structures of UL42 [40], ICP8 [41] and UL30 [42] have been solved. In particular, we lack a structural and molecular understanding of the helicase/primase complex of HSV-1 or any other herpesvirus. Here, we provide an overview of the state of knowledge of the ternary UL5/UL8/UL52 helicase primase complex. Insights from the molecular modelling of its subunits provide a detailed platform for discussion of the component functions, and prospects for targeted inhibition.

2. Structure and function relationships of subunits

The UL5/UL8/UL52 complex was initially identified by the observation of an enzyme with ATPase activity that is found specifically in HSV-1 infected Vero cells [43]. The partially purified approximately 440 kDa HSV-1 specific enzyme also exhibited GTPase and 5'-3' helicase activity [43]. Characterization of the purified proteins revealed that the subunits were composed of three polypeptides with apparent molecular weights of 95 000 (UL5), 120 000 (UL52) and 70 000 (UL8) daltons [44] that associated with a 1 : 1 : 1 apparent stoichiometry [45]. Subsequent characterization of the complex revealed that it possesses single-stranded (ss) DNA-dependent NTPase, DNA helicase and DNA primase activities [44,46].

2.1. UL5 helicase subunit

UL5 possesses seven motifs that are well-conserved in superfamily 1 (SF1) helicases including E. coli Rep, T4 bacteriophage Dda, eukaryotic Pif1 and SARS coronavirus ns13 (figure 2a) [51–53]. Helicases use the energy provided by DNA-stimulated NTP hydrolysis to achieve unwinding of duplex DNA. Thus, the catalytic reaction requires the coupling of the concerted events involving DNA binding, NTP binding, NTP hydrolysis and protein translocation along DNA (figure 2b). Consistent with a critical role for UL5 in the viral life cycle, mutations of the conserved UL5 helicase motifs (figure 2a) abolished the helicase activity of the complex [54,55] as well as viral replication in vivo [54]. Site-directed mutagenesis studies dissected the function of each motif during the pathway [55]. Residues in motif I (G102, K103) are directly involved in ssDNA stimulated NTP hydrolysis. Motif II
(D249, E250) is required for coupling of DNA binding to ATP hydrolysis. The mutations of the conserved residues in motif III (G290, Q294), motif IV (R345), motif V (T807, G815) and motif VI (Y836, R841) compromise ATPase activity, and also undermine helicase activity suggesting these motifs are involved in the coupling of DNA binding and ATP hydrolysis to the process of DNA unwinding. SF1 motifs IA and III have been proposed to determine the translocation polarity of helicases [56]. UL5 translocates on and unwinds the duplex DNA in a 5′–3′ direction [43], and it can use ATP or GTP as an energy source [43,46].

To better understand UL5 structure, we generated a homology model of UL5 using I-Tasser [47–49]. Figure 2c shows the model of UL5 based on the structure of the prototypical member of Pf1 family helicases, Saccharomyces cerevisiae (Sc) Pf1 protein (PDB: 5O6B) [50]. Similar to other SF1 helicases, ScPf1 has a 4-domain architecture composed of the 1A, 1B, 2A and 2B domains [57]. The seven conserved helicase

---

**Figure 2.** HSV-1 UL5 belongs to SF1 helicase superfamily. (a) Alignment of seven conserved motifs of HSV-1 UL5 (YP_009137079.1) with five members of SF1B superfamily: ScPf1 (NP_013650.1), UvrD (NP_418258.1), RecB (NP_417297.1), RecD (NP_417296.1), Rep (YP_026251.1), and with a representative of each subfamily of herpesviridae: Alpha (HSV-2; YP_009137156.1), Beta (HCMV; YP_081551.1) and Gammaherpesvirinae (EBV; YP_401681.1). The residues conserved among all proteins are indicated in red; the ones conserved only within herpesviruses in blue. Helicase motifs of UL5: motif I (95–108), IA (116–133), II (245–255), III (286–297), IV (342–350), V (807–816), VI (834–842). (b) Schematic steps for helicase catalysis. (c) I-Tasser modelling [47–49] of UL5 based on the ternary complex of truncated ScPf1237–780 with ssDNA and ADP.ALF4 (PDB:5O6B) [50]. UL5-specific regions are shown in grey, ssDNA is shown in green. (d) Close-up view of conserved residues from each motif forming active site of helicase.
motifs (figure 2a) map to the cleft separating domains 1A and 2A (figure 2c). In the crystal structure of ScPif1, DNA is bound by residues from the 1A, 2A and 2B domains [50]. ScPif1 displays a yeast-specific domain (2C), which protrudes from domain 2B [50]. The role of this insertion domain, which is not present in the crystal structures of the bacteriophages [58] and mammalian [59] Pif1 helicases, is not known. It has been suggested that domain 2C may coordinate the helicase function through protein–protein interactions in cells [50]. Interestingly, HSV-1 UL5 also seems to display a similar insertion (grey, figure 2c, left). Figure 2d shows the close-up view of the helicase core formed by conserved residues from each motif. The N- and C-terminal regions are the least conserved regions among SF1 helicases, which is also the case for UL5. The terminal regions of SF1 helicases determine the substrate specificity of helicases and/or mediate protein–protein interactions [56].

The heterodimer of UL5 and UL52 binds to short single-stranded DNA oligonucleotides, with a minimum length of 12 nucleotides to activate ATPase activity [60]. While the Herpes helicase prefers to bind forked DNA substrates and ssDNA/dsDNA junctions, herpes primase interacts with the ssDNA tail, as determined by photo-cross-linking experiments [61]. In addition, unwinding of duplex DNA in a 5′ to 3′ direction requires a 5′ single-stranded overhang of greater than 6 nucleotides [62]. The rate of unwinding was found to be 2 bp s⁻¹ [45], which is 25-fold lower than the estimated rate required for fork progression in vivo (50 bp s⁻¹) [63]. Nonetheless, this rate can be stimulated in vitro by ICF8 up to 60 bp s⁻¹ [64], as well as by UL8 [65,66], and by UL42 [67].

2.2. UL52 primase subunit

Primases can be divided into two superfamilies: DnaG-like and archaea-eukaryotic primase (AEP)-like primases [68,69]. HSV-1 primase belongs to the AEP superfamily that includes the AEP proper clade, the NCLDV–herpesvirus clade and the PrimPol proper clade [69,70] (figure 3a). All members of the AEP superfamily contain a catalytic core (AEP-like domain), which is distinct from the topoisomerase-primase (TOPPRIM) fold of the bacterial DnaG superfamily [68,69]. AEP-like domains have three signature motifs: motif I (DhE where h is a hydrophobic residue), motif II (sxH where s is a small residue, x could be any residue) and motif III (hDh) (figure 3b), all of which are conserved in herpes primase (figure 3b). Mutational analysis of motif I determined that D628 and D630 are critical for primase activity (figure 3b) [71,72]. Similar to other AEP primases, it is anticipated that the aspartate from motif III (D811) along with those from motif I (D628 and D630) will coordinate the catalytic divalent metals, while the arginine (R762) in motif II could interact with the incoming nucleotide during DNA polymerization [73].

UL52 also harbours a putative zinc finger domain (figure 3e) that is conserved in bacterial and bacteriophage primases, as well as human PrimPol (figure 3e) [74–77]. The putative UL52 zinc finger domain, Cys-X4-His-X29-Cys-X4-Cys, maps to residues 984–1033 (figure 3b) and mutation of the last two cysteines (C1023A and C1028A) significantly reduced DNA binding of the UL5/UL52 subcomplex as well as UL5/UL5/UL52 complex, and completely ablated its primase activity [78,79]. Furthermore, zinc finger mutants failed to support viral replication in vivo [79] underscoring a key role for this domain in mediating DNA binding, primase activity and viral replication.

In order to synthesize oligoribonucleotides on ssDNA, primases must first bind a DNA template, then their NTP substrates, and catalysis is initiated with the formation of a dinucleotide and inorganic pyrophosphate from two bound NTPs [80]. Additional NTPs are then incorporated at the 3′-end of the primer to generate full-length primers. Figure 3b depicts a general mechanism for primer synthesis. Herpes primase also follows these basic steps. UL52 can bind pyrimidine-rich DNA templates, such as poly-dT, and synthesizes 2–4 nucleotides [44,46]. However, for synthesis of RNA primers longer than 4 nucleotides, UL52 requires a specific tri-nucleotide motif on ssDNA template: 3′-deoxyguan-

2.3. UL8 subunit

The UL8 subunit of the heterotrimeric complex does not possess any known intrinsic catalytic activity [90,91] yet, its biological function is strictly required for the in vivo viral genome synthesis [14–16,92]. As a component of the heterotrimeric UL8–UL52–UL5 complex, UL8 is critical for the optimal activity of the primase [93–95], and the helicase [65,66]. Besides the requirement for the UL8 gene product in DNA synthesis, it also plays a biological role in facilitating the transport of UL5 and UL52 into the nucleus [96–98]. Unless all three subunits are co-expressed, they are mostly cytoplasmic as examined by immunofluorescence and do not localize to the cell nucleus [96,98]. Biochemical analyses of UL8 DNA binding showed that UL8 does not bind oligonucleotides smaller than 50 nucleotides [99], but it can bind to 90-nucleotide-long oligonucleotides [100]. Intriguingly, UL8 does stably associate with long ssM13 DNA, and forms protein-ssDNA filamentous structures [100]. The nucleoprotein filament formation is a property shared by many ssDNA-binding proteins involved
in recombination including archaeal RadA [101], bacterial RecA [102], HSV-1 ICP8 [103], KHSV ORF6 [24] and human Rad51 [104]. Compared to these proteins, UL8 filaments are distinct in that they are not helical filaments [100]. The significance of UL8 nucleofilament formation in an infected cell is currently unknown.

The C-terminal portion of UL8 was reported to be homologous to replicative B-family DNA polymerases [105], comprising the canonical three subdomains: fingers, palm and thumb [106]. Molecular modelling using Raptor X [107] of the full protein using the crystal structure of the ternary E. coli Pol II–DNA–dATP complex (PDB:3K57) [108] as a template structure suggests the polymerase fold is retained in UL8, but with significant divergence in its common polymerase motifs (figure 4). Out of three conserved catalytic aspartates located in the palm subdomain, DXXSLYPS from motif A and DTDS from motif C [110], only the first aspartate D502 from motif C (DGGA) is conserved in UL8 [105] (figure 4b). The palm subdomain of B-family polymerases also contains a conserved DNA-binding KKRY motif [111] that is absent in UL8 (figure 4b). The thumb subdomain in UL8 appears to also be divergent. However, the C-terminal 33 amino acids of UL8 (amino acids 717–750) are indispensable for HSV-1 replication [98] and expression plasmids encoding proteins carrying D671A and E673A mutations from the C-terminus displayed a replication-deficient phenotype in transient transfection experiments [109].

The N-terminal subdomains display the most structural diversity among polymerases [113], and dictate their specialized functions, such as translesion synthesis of Pol II [108] or RNAse H activity by UL30 [114]. On the other hand, the UL8 N-terminus carries residues essential for in vivo viral replication. For instance, deletion of 26 residues from the N-terminus (1–26) abolished DNA replication in transient transfection assays [98]. Another study reported that combined mutations of N-terminal R254, D255 and D257 residues caused a replication-deficient phenotype [109]. Thus, both N- and C-terminal regions appear to be indispensable for replication.

Overall, divergence of UL8 polymerase motifs suggests this subunit may play a DNA binding and structural scaffolding role as a component of the helicase–primase complex, rather than a direct catalytic role. More work is required to delineate the precise molecular functions of UL8.

3. Interactions between subunits

UL5, UL52 and UL8 together form a stable complex even in the presence of high salt (500 mM) [115]. All possible combinations of two-subunit heterodimers (UL5/UL52, UL5/UL8 and UL52/UL8) also form a stable complex and can be co-purified suggesting that each subunit interacts with each other. The basis for interactions between subunits has been largely explored [109,116,117]. Mutagenesis experiments identified a triple mutant (R640A–D642A–E644A), and a double mutant (R677A–R678A) of UL8 that lost the ability to bind UL52, suggesting that these residues interact with the UL52 subunit [109]. Further, the middle domain of UL8 (residues 422–887) interacts with the

Figure 3. HSV-1 UL52 belongs to AEP primases. (a) Domain organization of a representative member of AEP superfamily: HSV-1 UL52 (NCLDV-herpesvirus primase clade), human PrimPol (Prim-Pol clade) and HsPrim1 (AEP proper clade). The catalytic motifs within AEP-like domain are shown in blue. (b) Multiple sequence alignments of HSV-1 UL52 with human PrimPol, human Prim1, and with a representative of each subfamily of Herpesviridae. UL52 contains a conserved AEP domain (motif A, B and C), and a zinc finger domain. The residues conserved among all proteins are indicated in red; the ones conserved only within herpesviruses in blue. x, any residue; h, hydrophobic residue. NCBI’s RefSeq accession numbers: HSV-1 UL52 (YP_009137128.1), HsCCDC111 (NP_689896.1), Hs Prim1 (NP_000937.1), HSV-2 UL52 (YP_009137205.1), HCMV UL70 (YP_081518.1) and EBV BSLF1 (YP_401662.1). (c) Hypothetical mechanism of primase synthesis.

N-terminal subdomains display the most structural diversity among polymerases [113], and dictate their specialized functions, such as translesion synthesis of Pol II [108] or RNAse H activity by UL30 [114]. On the other hand, the UL8 N-terminus carries residues essential for in vivo viral replication. For instance, deletion of 26 residues from the N-terminus (1–26) abolished DNA replication in transient transfection assays [98]. Another study reported that combined mutations of N-terminal R254, D255 and D257 residues caused a replication-deficient phenotype [109]. Thus, both N- and C-terminal regions appear to be indispensable for replication.

Overall, divergence of UL8 polymerase motifs suggests this subunit may play a DNA binding and structural scaffolding role as a component of the helicase–primase complex, rather than a direct catalytic role. More work is required to delineate the precise molecular functions of UL8.
residues from the C-terminus of UL8 [117] (figure 5). The C-terminus of UL8 (718–750, minimally residues 727–739) also interacts with UL30 [118]. Additional observations reveal that UL8 interacts with both primase and polymerase via its C-terminal thumb-like subdomain (aa 583–750). Taken together, these data suggest that the UL8 C-terminus serves as a bridge to align the catalytic sites of primase and polymerase.

The UL52 N-terminus (aa 367–421) interacts with UL5 [117]. Less is known about how UL5 interacts with the other subunits, however, mutations in UL5 motif I (G102, K103) and motif IV (R345) eliminated helicase activity, but they did not abolish UL5 binding with either UL52 or UL8 [54]. The less conserved N- and C-terminal domains on UL5 could also be potential binding sites, as suggested for other helicases [56]. As will be discussed in §5 (below), a class of anti-herpes drugs targeting helicase/primase inhibitors (HPIs), are observed on both UL5 and UL52 [119]. Thus, these mutated residues possibly map to the UL5–UL52 interface (see below). Three resistance mutations were found in UL52. Two of them were located on the UL52 N-terminus, residues S364 and R367, which happen to be within the region shown to be essential for UL5 binding [117]. Indeed, UL52 mutants S364G and R367H were defective in UL5–UL52 complex formation [117]. The third resistance mutation A899 maps to the UL52 C-terminus [119]. The C-terminal mutant A899T did not affect the UL5–UL52 interaction [117]. Resistance mutants in UL5 (G352 V, M355I and K356T) are all downstream of motif I [119]. However, none of the UL5 variants had an effect on UL52 binding [117]. More in-depth analysis is required to explore protein binding sites on UL5.

4. Functional interdependence between subunits

A fully functional helicase/primase complex requires protein–protein interactions between UL5, UL8 and UL52.
4.1. UL5/UL8

In isolation, a UL5/UL8 binary complex does not exhibit DNA-dependent ATPase activity [95]. This observation might reflect the inability of UL5/UL8 to bind DNA substrates used in the helicase assay (dsDNA flanked by ssDNA regions). However, cross-linking assays showed that UL5/UL8 can still bind this substrate [95]. The pattern of cross-linking products formed with UL5/UL8 was different than the DNA–protein complex formed with UL5/UL8/UL52, which suggests that UL52 could modulate the way UL5 binds DNA and stimulates DNA-dependent ATPase activity of the complex [95].

4.2. UL52/UL8

Similar to UL5/UL8, a UL52/UL8 binary complex is not fully functional in that it does not synthesize RNA primers de novo on ssDNA template. This deficit is corroborated by cross-linking experiments suggesting that UL52/UL8 does not bind the primase substrate used [95]. Interestingly, UL52/UL8 does synthesize NTPs on an RNA primer-DNA template duplex that lacks the requirement for the primase initiation step. Thus, UL52/UL8 acts as a functional RNA polymerase, and the minimal complex can form phosphodiester bond without UL5. The elongation of an RNA primer-DNA template by the UL52/UL8 complex is kinetically less efficient than that of the UL5/UL8/UL52 complex. Even though $k_{cat}$ of the reaction was slightly decreased (8.1 h$^{-1}$ versus 2.3 h$^{-1}$), the catalytic efficiency ($k_{cat}/K_M$) of the subcomplex was approximately 20-fold decreased due to the increased $K_M$ for NTPs [95]. In summary, UL5 is required for the initiation of RNA primer synthesis, and maximal primase activity of the UL52/UL8/UL5 ternary complex.

4.3. UL5/UL52

The UL5 helicase and UL52 primase subunits are also interdependent. Unless these proteins are co-translated in the cells, they are apparently inactive [46,90], suggesting that the UL5/UL52 inter-subunit interactions are important for their proper folding, substrate interactions and/or activity. Mutational analysis of both subunits revealed that their interdependence is complex. Inactivation of the primase activity of UL52, by targeting the structure of the zinc-binding domain (C1023A and C1028A), also inactivates the helicase activity [78]. However, mutations targeting primase active site (D628 and D630), do not impair helicase activity [71,72]. Strikingly, inhibiting the helicase activity of UL5 by mutating the conserved helicase motifs (motifs I–VI; figure 2a) increases the primase activity up to 36-fold [55]. The basis for UL5/UL52 functional interdependence merits further investigation. It has been suggested that their mutual dependence may be due to their shared DNA interaction sites. The DNA-binding footprint of UL5 in the absence of UL52 is substantially different than that of the UL5/UL52 complex [95]. Hence, UL52 may impart structural rearrangements or expand the UL5 DNA–protein interface.

Figure 5. Map of interactions between subunits.
In conclusion, UL5 and UL52 display a complex relationship. The interdependence of helicase and primase activities, common in all DNA replication systems, is likely to be requisite to regulate the two activities at the replication fork, as the two activities must proceed in opposite directions along the same DNA strand. The molecular underpinnings of helicase/primase coupling in different replication systems requires more study.

4.4. UL5/UL52/UL8

Standard biochemical assays show that the subassembly of UL5/UL52 can synthesize primers on homopolymer DNA substrates of low sequence complexity (poly-dT) or unwind short duplex DNA as efficiently as the UL5/UL8/UL52 complex. However, in the absence of UL8, UL5/UL52 is not sufficient for in vivo DNA replication, primer synthesis on more complex DNA substrates (ssM13) [93], primase-coupled polymerase activity [87,93], lagging-strand synthesis [27,93] or unwinding of duplex DNA longer than 30 nucleotides [66]. Thus, HSV-1 DNA replication can occur only when all three subunits collaborate together.

5. Concluding remarks and outlook—helicase and primase as drug targets

Nucleoside analogues that target virus-encoded polymerase have dominated the anti-herpes drug industry for decades. The first nucleoside analogue drug, acyclovir, was discovered in 1977 by Elion et al. [120]. The first non-nucleoside analogue targeting helicase/primase complex (T157602) was reported in 1998 [121]. Since then, two HPIs have emerged as promising drug candidates: pritelivir (BAY 57–1293) [122] and amenamevir (ASP2151) [123]. Both drugs were shown to be more effective than acyclovir in animal models [123–126]. BAY 57–1293 successfully completed a phase II clinical trial for treatment of HSV-2 in 2016 [127,128]. As of 2021, the medicine has entered a phase III clinical study in Japan, in 2017 [130]. Amenamevir is currently used for the treatment of shingles (herpes zoster) and well tolerated in Japanese patients.

The efficacy of HPIs has been confounded by rapid development of viral resistance to these agents. Interestingly, resistance mutations were pre-existing in HSV-1 clinical isolates that had not been selected by the drugs [131]. The majority of variants found in strains resistant to BAY 57–1293 map to residues C-terminal of the conserved helicase motif IV (G352C, G352R, M355T, K356N, K356T, K356Q), with one mutation (N342 K) found within motif IV of UL5 [119] (figure 5). On the other hand, a single mutant virus (A899T) was found in the UL52 gene [132], suggesting that the mode of action of BAY 57–1293 is mainly via UL5. Nevertheless, a virus strain harbouring a K356T mutation on UL5 and an A899T mutation on UL52, conferred 2500-fold resistance to BAY 57–1293 [132]. Resistance mutations were also observed against ASP2151. The amino acid changes were G352 V and M355I in UL5; S364G and R367H on UL52 [133]. UL5 and UL52 are essential in the herpesvirus life cycle, and highly conserved among all members of herpesviridae. Therefore, compounds inhibiting the helicase/primase complex could be used as broad-spectrum drugs targeting all human herpesviruses. However, none of the current HPIs under development are effective against β- and γ-herpesvirinae [119]. In conclusion, the development of HPIs as an alternative treatment to the currently employed therapeutics requires more extensive work and will especially benefit from the resolution of the three-dimensional structure of the UL8-UL5-UL52 complex to facilitate rational drug design.

Data accessibility. This article has no additional data.

Authors’ contributions. O.B.—writing, original draft, R.S.W.—writing and editing.

Competing interests. We have no competing interests.

Funding. This work was supported by the intramural research programme of the US National Institutes of Health (NIH), National Institute of Environmental Health Sciences (NIEHS) grants 1Z01ES102765 to R.S.W.

References

1. Walker PJ et al. 2019 Changes to virus taxonomy and the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2019). Arch. Virol. 164, 2417–2429. (doi:10.1007/s00705-019-04306-w)

2. McGeoch DJ, Cook S, Dolan A, Jamieson FE, Telford EAR. 1995 Molecular phylogeny and evolutionary timescale for the family of mammalian herpesviruses. J. Mol. Biol. 247, 443–458. (doi:10.1006/jmbi.1995.0152)

3. McGeoch DJ, Dolan A, Ralph AC. 2000 Toward a comprehensive phylogeny for mammalian and avian herpesviruses. J. Virol. 74, 10401–10406. (doi:10.1128/jvi.74.22.10401-10406.2000)

4. Munawwar A, Singh S. 2016 Human herpesviruses as copathogens of HIV infection, their role in HIV transmission, and disease progression. J. Lab. Physicians 8, 005–018. (doi:10.4103/0974-2727.176228)

5. Schiffer JT, Corey L. 2013 Rapid host immune response and viral dynamics in herpes simplex virus-2 infection. Nat. Med. 19, 280–290. (doi:10.1038/nm.3103)

6. Britt WJ. 2017 Congenital human cytomegalovirus immunity. J. Virol. 91, e02392-16. (doi:10.1128/JVI.02392-16)

7. Clark DA. 2002 Human herpesvirus 6 and human herpesvirus 7: emerging pathogens in transplant patients. Int. J. Hematol. 76, 246–252. (doi:10.1007/BF03165124)

8. Shannon-Lowe C, Rickinson AB, Bell AI. 2017 Epstein-barr virus-associated lymphomas. Phil. Trans. R. Soc. B 372, 20160271. (doi:10.1098/rstb.2016.0271)

9. Mesri EA, Cesaran E, Boshoff C. 2010 Kaposi’s sarcoma and its associated herpesvirus. Nat. Rev. Cancer 10, 707–719. (doi:10.1038/nrc2888)

10. De Clercq E, Li G. 2016 Approved antiviral drugs over the past 50 years. Clin. Microbiol. Rev. 29, 695–747. (doi:10.1128/CMR.00102-15)

11. Schmidt S, Bohn-Wippert K, Schlattmann P, Zell R, Sauerbrei A. 2015 Sequence analysis of herpes simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance. Antimicrob. Agents Chemother. 59, 4938–4945. (doi:10.1128/AAC.00977-15)

12. Grumpecker CS. 1996 Drug therapy: ganciclovir. N. Engl. J. Med. 335, 721–729. (doi:10.1056/NEJM199609053351007)
13. Whisnant AW et al. 2020 Integrative functional genomics decodes herpes simplex virus 1. Nat. Commun. 11, 2038. (doi:10.1038/s41467-020-15992-5)

14. McGeoch DJ, Dalrymple MA, Dolan A, McBride D, Perry LJ, Taylor P, Challberg MD. 1988 Structures of herpes simplex virus type 1 genes required for replication of virus DNA. J. Virol. 62, 444–453. (doi:10.1128/jvi.62.2.444-453.1988)

15. Wu CA, Nelson NJ, McGeoch DJ, Challberg MD. 1988 Identification of herpes simplex virus type 1 genes required for origin-dependent DNA synthesis. J. Virol. 62, 435–443. (doi:10.1128/jvi.62.2.435-443.1988)

16. Olivo PD, Nelson NJ, Challberg MD, Wu CA, Nelson NJ, McGeoch DJ, Challberg MD. 1989 Herpes simplex virus type 1 gene products required for DNA replication: identification and overexpression. J. Virol. 63, 196–204. (doi:10.1128/jvi.63.1.196-204.1989)

17. Loregian A, Rigatti R, Murphy M, Schievana E, Palu G, Marsden HS. 2003 Inhibition of human cytomegalovirus DNA polymerase by C-terminal peptides from the UL54 subunit. J. Virol. 77, 8336–8344. (doi:10.1128/jvi.77.15.8336-8344.2003)

18. Tsurumi T, Kobayashi A, Tamai K, Daikoku T, Kurachi K. 2003 Purification, characterization, and action on DNA polymerase catalytic subunit: differences in structure and function relative to unliganded UL44. Proc. Natl Acad. Sci. USA 97, 3896–3900. (doi:10.1073/pnas.97.8.3896)

19. Stengel G, Kuchta RD. 2011 Coordinated leading and lagging strand DNA synthesis in vitro by a reconstituted herpes simplex virus type 1 replisome. Proc. Natl Acad. Sci. USA 108, 5142–5147. (doi:10.1073/pnas.1010935108)

20. Appleton BA, Loregian A, Filman DJ, Coen DP, Hogle JM. 2006 Crystal structure of the herpesvirus DNA polymerase and its processivity factor. J. Virol. 80, 2628–2632. (doi:10.1128/JVI.80.7.2628-2632.2006)

21. Appleton BA, Brooks J, Loregian A, Filman DJ, Coen DM, Hogle JM. 2004 The cytomegalovirus DNA polymerase subunit UL44 forms a C clamp-shaped dimer. Mol. Cell 15, 233–244. (doi:10.1016/S1097-2765(04)00618-X)

22. Murayama K et al. 2009 Crystal structure of Epstein-Barr virus DNA polymerase processivity factor BMRF1. J. Biol. Chem. 284, 35 896–35 905. (doi:10.1074/jbc.M901518200)

23. Tsurumi T, Kobayashi A, Tamai K, Yamada H, Daikoku T, Yamashita Y, Nishiyama Y. 1996 Epstein-Barr virus single-stranded DNA-binding protein: purification, characterization, and action on DNA synthesis by the viral DNA polymerase. Virology 222, 352–364. (doi:10.1006/viro.1996.0432)

24. Ozgur S, Griffith J. 2014 Interaction of Kaposis’s sarcoma-associated herpesvirus ORF6 protein with single-stranded DNA. J. Virol. 88, 8687–8695. (doi:10.1128/jvi.03652-13)

25. Ligat G, Re S Da, Alain S, Hantz S. 2018 Identification of amino acids essential for viral replication in the HCMV helicase-primase complex. Front. Microbiol. 9, 2483. (doi:10.3389/fmicb.2018.02483)

26. Thiery E, Brennich M, Round A, Buissin M, Burmeister WP, Huting S. 2015 Production and characterisation of Epstein-Barr virus helicase–primase complex and its accessory protein BBLF3/2. Virus Genes 51, 171–181. (doi:10.1007/s11262-015-1233-6)

27. Falkenberg M, Lehman IR, Elias P. 2000 Leading and lagging strand DNA synthesis in vitro by a reconstituted herpes simplex virus type 1 replisome. Proc. Natl Acad. Sci. USA 97, 3896–3900. (doi:10.1073/pnas.97.8.3896)

28. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2008 I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 464. (doi:10.1186/1471-2105-9-40)

29. Roy A, Kucukural A, Zhang Y. 2010 I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738. (doi:10.1038/nprot.2010.5)

30. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2014 The I-TASSER suite: protein structure and function prediction. Nat. Methods 12, 7–8. (doi:10.1038/nmeth.2123)

31. Lu KY, Chen W-F, Rety S, Liu N-N, Wu W-Q, Dai Y-X. 2019 Herpes simplex virus type 1 helicase-primase: physical and catalytic properties. J. Biol. Chem. 266, 4484–4488. (doi:10.1074/jbc.M118.001286)

32. Dodson MS, Crute JJ, Buckner RC, Lehman IR. 1989 Overexpression and assembly of the herpes simplex virus type 1 helicase-primase in insect cells. J. Biol. Chem. 264, 20 835–20 838. (doi:10.1074/jbc.264.35.20838)

33. Zhang Y. 2008 I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9, 40. (doi:10.1186/1471-2105-9-40)

34. Roy A, Kucukural A, Zhang Y. 2010 I-TASSER: a unified platform for automated protein structure and function prediction. Nat. Protoc. 5, 725–738. (doi:10.1038/nprot.2010.5)

35. Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. 2014 The I-TASSER suite: protein structure and function prediction. Nat. Methods 12, 7–8. (doi:10.1038/nmeth.2123)

36. Lu KY, Chen W-F, Rety S, Liu N-N, Wu W-Q, Dai Y-X. 2019 HERPES: Insights into the structural and mechanistic basis of multifunctional S. cerevisiae pif3p helicase. Nucleic Acids Res. 46, 1486–1500. (doi:10.1093/nar/gkx1217)

37. Hodgman TC. 1988 A new superfamily of replicative proteins. Nature 333, 22–23. (doi:10.1038/33302260)

38. Gorbalenya AE, Koonin EV. 1993 Helicases: amino acid sequence comparisons and structure-function relationships. Curr. Opin. Struct. Biol. 3, 419–429. (doi:10.1016/0959-440X(93)80116-2)
null
129. Poole CL, James SH. 2018 Antiviral therapies for herpesviruses: current agents and new directions. *Clin. Ther.* **40**, 1282–1298. (doi:10.1016/j.clinthera.2018.07.006)

130. Kawashima M, Nemoto O, Honda M, Watanabe D, Nakayama J, Imakuku S, Kato T, Katsuramaki T. 2017 Amenamevir, an oligonucleotide helicase–primase inhibitor, for treatment of herpes zoster: a randomized, double-blind, valaciclovir-controlled phase 3 study. *J. Dermatol.* **44**, 1219–1227. (doi:10.1111/1346-8138.13948)

131. Sukla S, Biswas S, Birkmann A, Lischka P, Zimmermann H, Field HJ. 2010 Mismatch primer-based PCR reveals that helicase–primase inhibitor resistance mutations pre-exist in herpes simplex virus type 1 clinical isolates and are not induced during incubation with the inhibitor. *J. Antimicrob. Chemother.* **65**, 1347–1352. (doi:10.1093/jac/dkq135)

132. Biswas S, Kleymann G, Swift M, Tiley LS, Lyall J, Aguirre-Hernández J, Field HJ. 2008 A single drug-resistance mutation in HSV-1 UL52 primase points to a difference between two helicase–primase inhibitors in their mode of interaction with the antiviral target. *J. Antimicrob. Chemother.* **61**, 1044–1047. (doi:10.1093/jac/dkn057)

133. Chono K, Katsumata K, Kontani T, Shiraki K, Suzuki H. 2012 Characterization of virus strains resistant to the herpes virus helicase-primase inhibitor ASP2151 (Amenamevir). *Biochem. Pharmacol.* **84**, 459–467. (doi:10.1016/j.bcp.2012.05.020)